TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27

Chengpeng Yu, Dean Rao, He Zhu, Qiumeng Liu, Wenjie Huang, Long Zhang, Huifang Liang, Jia Song, and Zeyang Ding

BACKGROUND. Tryptophan-2,3-dioxygenase (TDO2) converts tryptophan into kynurenine in the initial limiting step of the kynurenine pathway. During the past decade, the overexpression of TDO2 has been found in various human tumors. However, the role of TDO2 in hepatocellular carcinoma is controversial, and we sought to clarify it in this study.

METHODS. Western blot analysis and immunochemistry were used to detect the expression of TDO2 in human tissue specimens. The effect of TDO2 on cell proliferation in vitro was assessed using CCK8 and colony formation assays, and a xenograft mouse model was used to detect the effect of TDO2 on tumor growth in vivo. Flow cytometry was used to assess the cell cycle status.

RESULTS. Low TDO2 expression was found in HCC and was associated with poor prognosis and adverse clinical outcomes. Conversely, TDO2 could restrain the proliferation of HCC cells in vivo and in vitro. Furthermore, TDO2 upregulated the expression of p21 and p27, inducing cell-cycle arrest.

CONCLUSIONS. The loss of TDO2 expression in HCC was correlated with a poor prognosis and adverse clinical outcomes. At the same time, TDO2 could restrain the growth of HCC in vivo and in vitro. The results indicate that TDO2 is a potential biomarker and therapeutic target for HCC.

1. Introduction

As the sixth most commonly diagnosed type of cancer worldwide, hepatocellular carcinoma (HCC) imposes a heavy burden on global health [1]. HCC is an aggressive cancer and often diagnosed at an advanced stage, which results in a poor prognosis because surgical resection is only effective in the early stage [2]. Although combining immune checkpoint inhibitors with antivascular endothelial growth factor (VEGF) antibodies demonstrated a promising survival benefit for some patients with advanced HCC, this combined treatment is not effective for all advanced HCC patients [3, 4]. Hence, it is vital to explore and understand the complex pathogenesis of HCC to develop new therapeutic targets and biomarkers for the early diagnosis and treatment of HCC.

Tryptophan-2,3-dioxygenase (TDO2) converts tryptophan into kynurenine in the initial limiting step of the kynurenine pathway [5]. Under physiological conditions, TDO2 is only expressed in the liver, where it is responsible for tryptophan metabolism. However, TDO2 can also be expressed in other tissues, such as the placenta, epididymis, and testes [6, 7]. During the past decade, TDO2 was found to be overexpressed in various tumors, such as glioma, breast cancer, basal cell carcinoma, melanoma, cervical cancer, and colorectal cancer [5, 8–13]. As the depletion of tryptophan and the
production of its downstream metabolites can restrain the proliferation of immune cells, the overexpression of TDO2 in tumors was considered to promote tumor immune escape and stimulate cancer metastasis [5, 12, 14]. However, the role of TDO2 in hepatocellular carcinoma is controversial. Some studies reported that TDO2 is highly expressed in hepatocellular carcinoma [15, 16], while others implied that TDO2 in HCC tumors is expressed at lower levels than in adjacent tissues [5, 17].

In this study, we firstly used UALCAN (http://ualcan.path.uab.edu) to conveniently access clinical data from TCGA for an analysis of the differences in TDO2 mRNA levels between normal samples and HCC as well as their relationship to clinicopathological parameters [18]. The results revealed lower TDO2 mRNA levels in HCC than in normal tissues. We then examined TDO2 protein expression in a clinical tissue microarray (TMA) and tissue specimens of HCC using immunohistochemical (IHC) staining and western blot analysis, which revealed lower TDO2 protein levels in tumor specimens than in normal tissues. At the same time, Kaplan-Meier survival analysis showed that the loss of TDO2 expression was associated with shorter survival of HCC patients. Furthermore, we also analyzed the roles of TDO2 in HCC cell lines both in vivo and in vitro. Overexpression of TDO2 restrained the proliferation of HCC cells, resulting in cell-cycle arrest in the G1 phase. Additionally, TDO2 was found to upregulate the expression of p21 and p27 while reducing CDK2 and CDK4 expression.

2. Patients and Methods

2.1. Patients. Primary HCC tissues and adjacent matched normal tissues from a total of 116 patients who underwent tumor resection at the Hepatic Surgery Center, Tongji Hospital of Huazhong University of Science and Technology (HUST) (Wuhan, China) between 2012/2/16 and 2014/4/1 were used in this study. In addition, 40 paired fresh specimens of HCC tissues and adjacent normal tissues from the specimen collection were used for western blot analysis. Overall survival (OS) and disease-free survival (DFS) was defined as the time from the first surgery to death or recurrence/metastasis, respectively.

2.2. Western Blot Analysis. Cold RIPA lysis buffer (Boster Biological Technology, Wuhan, Hubei, China) with a protease inhibitor cocktail was used to extract total protein from tissue samples. The protein concentration was measured by using a bicinchoninic acid (BCA) protein quantification kit (Wuhan Boster Biological Technology, Ltd., Wuhan, China). The proteins were separated on a 10% acrylamide SDS-PAGE gel and transferred to a PVDF membrane (Merck Millipore, Billerica, MA). The membrane was blocked with 5% BSA and incubated with appropriately diluted primary antibodies against TDO2 (#H00006999-D01P, Abnova), p21 (#2947, Cell Signaling Technology), p27 (#3686, Cell Signaling Technology), p53 (#2524, Cell Signaling Technology), CDK2 (sc-748, Santa Cruz), CDK4 (#1290, Cell Signaling Technology), and GAPDH (KC-5G4; Kang-Chen BioTech Co., Ltd.) overnight at 4°C. The membrane was then washed with phosphate-buffered saline (PBS) and incubated with HRP-labelled goat anti-rabbit or anti-mouse secondary antibodies (ab6702, ab205719, 1:2000, Abcam) for 1 h at room temperature. An enhanced chemiluminescence (ECL) reagent (Merck Millipore, Billerica, MA) was used to develop the blots. Image Lab Software was used to quantify the grayscale density of the protein bands.

2.3. Immunohistochemistry. Paraffin sections of 4 μm thickness were used for TDO2 detection. Xylene and a gradient of ethanol solutions were used to dewax and gradually hydrate the tissue sections. For antigen retrieval, the slides were heated in a steam cooker for 10–15 min in 0.01 mol/l citrate buffer (pH 6.0). Then, the slides were washed with PBS (pH 7.4), and endogenous peroxidases were blocked by incubation in 1 × TBS with 0.3% H2O2 for 20 min at room temperature. Then, the primary anti-TDO2 polyclonal antibody was added to the samples and incubated at 4°C overnight. On the next day, 1 × TBS was used to wash the slides thoroughly, and a fresh substrate solution containing dianobenzidine was used to visualize the antibody binding. Two independent pathologists who were blinded to the patient information assessed the immunohistochemical staining. Each specimen was assessed and scored according to the percentage of stained cells (0–5% = 0, 5–25% = 1, 26–50% = 2, 51–75% = 3, and 76–100% = 4) and intensity of positive tumor cells (none = 0, weak = 1, intermediate = 2, and strong = 3) and summed up to calculate the immunostaining score of TDO2 expression. The low- and high-level expressions were judged based on overall scores of <6 and ≥6, respectively.

2.4. Flow Cytometry. Propidium Iodide Staining Solution (BD Pharmingen™, New Jersey, USA) was used for flow cytometry. Cells were trypsinized and suspended at 1 × 10^5 cells/ml, followed by staining with a fluorescent antibody and propidium iodide (PI) at room temperature in the dark for 30 min. After incubation, the cells were centrifuged at 200g and resuspended for analysis on a FACS instrument (BD Bioscience, San Jose, CA).

2.5. Cell Lines and Culture Conditions. HLF cells were obtained from our laboratory, while HEK293 and HepG2 cells were ordered from the China Center for Type Culture Collection (CCTCC, Wuhan, China). All cells were cultured at 37°C in Dulbecco’s Modified Eagle’s Medium (DMEM) (high glucose) (HyClone, USA) supplemented with 10% fetal bovine serum (Bovogen, Argentina) in a humidified atmosphere comprising 5% CO2.

2.6. Plasmids and Lentivirus. The plenti-CMV-Puro, pMD2.G, gagpol, and psPAX2 plasmids (Addgene plasmids #17448 #12259, #35614 and 12260; Addgene, Cambridge, MA, USA) were used for gene expression and lentivirus packaging. The CDS of the td2 gene was amplified by PCR and subcloned into the lentiviral vector plenti-CMV-Puro. HEK293 cells were cotransfected with psPAX2 and pMD2.G, pLenti-CMV-Puro, or pLenti-CMV-TDO2-Puro to produce lentivirus virions. We collected the virions in the supernatant at 48 and 72 hr posttransfection and passed them through a
0.45 μm filter before storage at -80°C. The resulting lentivirus stock was used to transfect HLF and HepG2 cells to establish stable cell lines.

2.7. Cell Proliferation and Colony Formation Assays. A total of 1000 cells in 100 μl of medium was seeded into each well of the 96-well plate. After culturing for 24, 48, 72, 96, and 120 h, 100 μl of CCK8 solution (Cell Counting Kit-8; Beyotime Institute of Biotechnology, Shanghai, China) in each well was incubated for 2 h, followed by measurement of the absorbance at 450 nm using a microplate reader (BioTek, Winooski, VT, USA). For the colony formation assay, each
well of a 6-well plate was seeded with 1000 cells, which were cultured for 2 weeks at 37°C. The resulting colonies were fixed with 20% methanol and stained using 0.1% crystal violet, followed by manual counting under a conventional optical microscope. All experiments were done in triplicate.

2.8. Tumor Growth Assay In Vivo. All animal experiments were conducted with the approval of the Ethic Committee of Tongji Hospital of HUST and were in accordance with the animal welfare guidelines of the People’s Republic of China National Standard (GB/T 35,892-2018). For the xenograft model, 4-week-old male BALB/c athymic nude mice were randomly divided into 2 groups (n = 6 per group) and injected subcutaneously with 1.5 × 10^6 tumor cells in 100 μl of serum-free DMEM into the flank. Every 3 days, the development of the tumors was observed, and the mice were sacrificed after the indicated number of days. The tumors were then removed, photographed, weighed, and measured.

2.9. Statistical Analysis. Statistical analyses were conducted using SPSS 22.0 (IBM Corp., USA). The χ² test was used to evaluate the statistical significance of the correlation between clinicopathological variables and TDO2 expression.

Figure 2: TDO2 was downregulated in HCC. (a) Western blot analysis of TDO2 expression in 40 paired fresh specimens of HCC and normal tissues. (b) Immunochemistry analysis of TDO2 expression in 116 pairs of primary HCC tissues and adjacent normal tissues. (c) Column chart of western blot analysis of TDO2 expression in 40 paired fresh specimens of HCC tissues and adjacent normal tissues. (d) Dot chart of immunochemistry analysis of TDO2 expression in 116 pairs of primary HCC tissues and adjacent normal tissues. (e) Kaplan-Meier analysis of overall survival in patients with high and low TDO2 expression. (f) Kaplan-Meier analysis of disease-free survival in patients with high and low TDO2 expression.
3. Results

3.1. The Loss of TDO2 Expression in HCC Is Related to Poor Clinical Outcomes. In spite of its widely acknowledged effects in many other cancers, the role of TDO2 in HCC is controversial. Consequently, we first used data from TCGA to detect the expression of TDO2 in HCC. UALCAN was used to identify TDO2 mRNA levels in 24 types of cancers compared to normal tissues in TCGA [18]. As shown in Figures 1(a) and 1(b), the expression of TDO2 was upregulated in most cancers, but it was downregulated in cholangiocarcinoma, hepatocellular carcinoma, and pancreatic adenocarcinoma (Figures 1(a) and 1(b)). As TDO2 is only expressed in the liver under physiological conditions, we wished to explore the expression of TDO2 in HCC. We used 40 paired fresh HCC specimens and adjacent normal tissues for western blot and tissue microarray analyses of the expression of TDO2. The results indicated that TDO2 expression was downregulated in HCC (Figures 2(a)–2(d)). Furthermore, we used UALCAN to analyze the relationship between TDO2 expression and clinicopathological characteristics in HCC, which revealed that low TDO2 expression was correlated with a low tumor grade, advanced cancer stage, and cancer metastasis (Figures 1(c)–1(e)). Then, TDO2 expression in tumors from 116 HCC patients was assessed by microarray IHC analysis. Subsequently, the patients were divided into low- and high-expression groups according to the immunostaining score to explore the relationship between TDO2 expression and clinical outcomes. The results of regression analysis indicated that low TDO2 expression was associated with tumor size \((P = 0.011)\), tumor stage (BCLC stage \(P = 0.019\) and TNM stage \(P = 0.027\)), tumor differentiation \((P = 0.038)\), and tumor recurrence \((P = 0.041)\). However, low TDO2 expression was not associated with age, sex, ALT level, AST level, serum AFP level, tumor number, and tumor capsule (Table 1). Additionally, Kaplan-Meier survival analysis was used to investigate the relationship between the expression of TDO2 and overall survival (OS) or disease-free survival (DFS). The results demonstrated that patients with low TDO2 expression had shorter OS \((P = 0.0384)\) (Figure 2(e)) and DFS \((P = 0.0194)\) (Figure 2(f)).

3.2. Overexpression of TDO2 Inhibited Cell Proliferation In Vitro. Since the loss of TDO2 expression was correlated with adverse clinical outcomes and a poor prognosis in HCC, it is possible that TDO2 acts as a tumor suppressor. Accordingly, we wanted to investigate the effect of TDO2 on tumorigenesis in HCC cell lines and used lentiviral vectors to transduce HLF and HepG2 cells to establish stable cell lines with TDO2 overexpression. The expression of TDO2 was detected by WB (Figures 3(a) and 3(b)). The CCK8 assay indicated that TDO2 overexpression restrained the proliferation of HLF and HepG2 cells (Figures 3(c) and 3(d)). At the same time, the overexpression of TDO2 in HLF and HepG2 cells reduced their colony formation ability (Figures 3(e) and 3(f)). Taken together, these results show that TDO2 restrained the proliferation of HCC cell lines in vitro.

3.3. Overexpression of TDO2 Induced Cell Cycle Arrest and Upregulated the Expression of p21 and p27 In Vitro. As the results of the CCK8 and colony formation assays demonstrated that the overexpression of TDO2 could restrain the

| Features                     | Total | Normal expression | Low expression | \(P\) value |
|------------------------------|-------|-------------------|----------------|-------------|
| **Sex**                      |       |                   |                |             |
| Male                         | 95    | 43                | 52             | 0.324       |
| Female                       | 21    | 12                | 9              |             |
| **Age (years)**              |       |                   |                |             |
| \(\leq 50\)                  | 52    | 23                | 31             | 0.254       |
| \(>50\)                      | 64    | 34                | 30             |             |
| **ALT**                      |       |                   |                |             |
| \(<70\)                      | 106   | 49                | 57             | 0.615       |
| \(\geq 70\)                  | 10    | 6                 | 4              |             |
| **AST**                      |       |                   |                |             |
| \(<70\)                      | 101   | 47                | 54             | 0.830       |
| \(\geq 70\)                  | 15    | 8                 | 7              |             |
| **Serum AFP (ng/ml)**        |       |                   |                |             |
| \(<400\)                     | 62    | 25                | 37             | 0.101       |
| \(\geq 400\)                 | 54    | 30                | 24             |             |
| **Tumor size (cm)**          |       |                   |                |             |
| \(\leq 5\)                   | 39    | 26                | 13             | 0.011       |
| \(>5\)                       | 77    | 32                | 45             |             |
| **Tumor number**             |       |                   |                |             |
| Single                       | 90    | 59                | 41             | 0.127       |
| Multiple                     | 26    | 11                | 15             |             |
| **BCLC stage**               |       |                   |                |             |
| \(0+A\)                      | 75    | 48                | 27             | 0.019       |
| \(B+C\)                      | 41    | 17                | 24             |             |
| **TNM stage**                |       |                   |                |             |
| \(I + II\)                   | 86    | 46                | 40             | 0.027       |
| \(III + IV\)                 | 30    | 9                 | 21             |             |
| **Differentiation**          |       |                   |                |             |
| Well/moderate               | 73    | 40                | 33             | 0.038       |
| Poor                         | 43    | 15                | 28             |             |
| **Vascular invasion**        |       |                   |                |             |
| Yes                          | 23    | 7                 | 16             | 0.069       |
| No                           | 93    | 48                | 45             |             |
| **Tumor capsule**            |       |                   |                |             |
| Absent                       | 55    | 26                | 29             | 0.977       |
| Present                      | 61    | 29                | 32             |             |
| **Recurrence**               |       |                   |                |             |
| Yes                          | 58    | 22                | 36             | 0.041       |
| No                           | 58    | 33                | 25             |             |
proliferation of HCC cell lines, flow cytometry and western blot analyses were used to explore the effects of TDO2 on the cell cycle and related proteins, respectively. The results of flow cytometry demonstrated that the overexpression of TDO2 increased the percentage of cells in the G1 phase in both the HLF and HepG2 HCC cell lines, leading to cell cycle arrest (Figures 4(a)–4(d)). Furthermore, the results of western blot analysis showed that the overexpression of TDO2 enhanced the expression of p21 and p27 while reducing the expression of CDK2 and CDK4 (Figures 4(e) and 4(f)). In conclusion, the results indicate that TDO2 might induce cell cycle arrest via the upregulation of p21 and p27 expression.

3.4. TDO2 Overexpression Inhibited Tumor Growth In Vivo.

In order to further verify the influence of TDO2 on tumor growth in vivo, we subcutaneously injected HLF and HepG2 cells stably transfected with the TDO2 expression vector or an empty vector into nude mice. At 21 days after subcutaneous injection, the growth and weight of tumors comprising the TDO2-overexpressing stable cell lines were reduced compared to those of the empty vector group (Figures 5(a)–5(d)).
At the end of the experiment, the subcutaneous tumor tissues were subjected to HE staining for histopathological assessment. Representative photographs of HE staining are shown in Figures 5(e) and 5(f). Furthermore, IHC was used to detect the expression of the cell proliferation marker Ki67 in the subcutaneous tumor tissue. The IHC staining showed that the expression of Ki67 in the TDO2 overexpression group was lower than that in the control group (Figures 5(g) and 5(h)).

4. Discussion

TDO2 is a heme-containing enzyme responsible for the oxidation of tryptophan [5]. Under physiological conditions,
TDO2 is only expressed in the liver, where it is responsible for tryptophan metabolism [19]. Since TDO2 was firstly reported to be overexpressed in glioma, where it plays a tumor promoting role, increasing numbers of studies reported that TDO2 was overexpressed in other tumors, such as breast cancer, basal cell carcinoma, melanoma, cervical cancer, and colorectal cancer, where it is also involved in tumor development [5, 10, 13, 14]. However, the role of TDO2 in HCC is controversial. Some studies implied that TDO2 was downregulated in HCC [5, 17], while other studies indicated that TDO2 may be overexpressed in HCC [15]. In this study, we firstly used UALCAN to analyze the relative TDO2 mRNA levels in normal samples and HCC tumors and found that TDO2 mRNA expression in HCC samples was lower than in healthy tissues. Furthermore, we used WB and IHC to detect the expression of TDO2 in 40 paired fresh specimens of HCC and a tissue microarray, respectively, which confirmed that TDO2 was downregulated in HCC. At the same time, the loss of the TDO2 expression was correlated with a poor prognosis and adverse clinical outcomes. These results implied that TDO2 may function as a tumor suppressor in HCC, which is in contrast to the current viewpoint that TDO2 functions as a tumor promoter. However, it should be noted that TDO2 is normally only

![Image of macroscopic images and graphs](image-url)
expressed in the liver where it is responsible for tryptophan metabolism. This in turn may indicate that its role in liver cancer is different from other tumors. Alternatively, the inconsistency of antibody staining and the cutoffs used to assign patients to high or low TDO2 expression groups might account for this discrepant finding.

As the loss of TDO2 was correlated with a poor prognosis and adverse clinical outcomes in HCC, we further explored the effect of TDO2 on HCC cell proliferation. We found that TDO2 could restrain the proliferation of HCC line cells and induce cell-cycle arrest by enhancing the expression of p21 and p27 while decreasing CDK2 and CDK4 expression. As most studies on the roles of TDO2 in tumors focus on tumor immune evasion, there are relatively few studies on the effect of TDO2 on the proliferation of tumor cells. As the depletion of tryptophan and accumulation of kynurenine can restrain the proliferation of T cells, TDO2 expression was also found to restrain the proliferation of T cells [5]. At the same time, IDO1, the isozyme of TDO2, was reported to induce cell cycle arrest by upregulating the expression of p27 via the kynurenine-AHR axis [20]. Accordingly, TDO2 might upregulate the expression of p21 and p27 via the kynurenine-AHR axis, but this conjecture needs further investigation.

Under normal physiological conditions, TDO2 is only expressed in the liver, while the expression of TDO2 is lost in HCC. At the same time, the expression of TDO2 is upregulated in most cancer types [9, 10, 13, 14]. Hence, the underlying mechanisms and effects to the loss of TDO2 expression in HCC merit further attention. As the promoter of the tdo2 gene contains two glucocorticoid-responsive elements (GREs), TDO2 can be upregulated by glucocorticoids [21]. However, plasma glucocorticoid levels were reported to be practically the same in hepatocarcinoma patients and healthy controls or portal hypertension patients without hepatocarcinoma [22]. It is also possible that the abnormal expression of 11β-HSD1 and 11β-HSD2 in HCC, two critical enzymes that regulate the activity of glucocorticoids in the liver, accounts for the loss of TDO2 expression, but this hypothesis needs further investigation [23, 24].

5. Conclusions

In summary, our data demonstrate that TDO2 expression is reduced in HCC, and low TDO2 expression was correlated with a poor prognosis and adverse clinical outcomes. At the same time, TDO2 overexpression could restrain the proliferation of HCC cells in vivo and in xenograft mouse models in vitro. TDO2 overexpression induced cell cycle arrest by upregulating the expression of p21 and p27. These data indicate that TDO2 might serve as a biomarker for HCC.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethical Approval

The studies involving human participants were reviewed and approved by the Research Ethics Committee of Tongji Hospital of Huazhong University of Science and Technology (China).

Consent

The patients/participants provided their written informed consent to participate in this study.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Authors’ Contributions

YC performed the research and wrote the first draft. RD, ZH, and LQ collected and analyzed the data. DZ, SJ, and LH are the guarantors. All authors contributed to the design and interpretation of the study as well as to the revised drafts.

Acknowledgments

This research was supported by grants from the National Natural Science Foundation of China (Nos. 81871911 to W.H. and 81874065 to D.Z.).

References

[1] P. Rawla, T. Sunkara, P. Muralidharan, and J. P. Raj, “Update in global trends and aetiology of hepatocellular carcinoma,” Wspolczesna Onkologia, vol. 22, no. 3, pp. 141–150, 2018.
[2] A. Forner, M. Reig, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 391, no. 10127, pp. 1301–1314, 2018.
[3] D. Neureiter, S. Stintzing, T. Kiesslich, and M. Ocker, “Hepatocellular carcinoma: therapeutic advances in signaling, epigenetic and immune targets,” World Journal of Gastroenterology, vol. 25, no. 25, pp. 3136–3150, 2019.
[4] R. S. Finn, S. Qin, M. Ikeda et al., “Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma,” The New England Journal of Medicine, vol. 382, no. 20, pp. 1894–1905, 2020.
[5] C. A. Opitz, U. M. Litzenburger, F. Sahm et al., “An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor,” Nature, vol. 478, no. 7368, pp. 197–203, 2011.
[6] A. Britan, V. Maffre, S. Tone, and J. R. Drevet, “Quantitative and spatial differences in the expression of tryptophan-metabolizing enzymes in mouse epididymis,” Cell and Tissue Research, vol. 324, no. 2, pp. 301–310, 2006.
[7] Y. Minatogawa, S. Suzuki, Y. Ando, S. Tone, and O. Takikawa, “Tryptophan pyrrole ring cleavage enzymes in placenta,” Advances in Experimental Medicine and Biology, vol. 527, pp. 425–434, 2003.
[8] E. T. Tina, S. Prosen, S. Lennholm, G. Gasparty, M. Lindberg, and A. Gothlin Eremo, “Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma,” The British Journal of Dermatology, vol. 180, no. 1, pp. 130–140, 2019.
[9] M. Terai, E. Londin, A. Rochani et al., “Expression of tryptophan 2,3-dioxygenase in metastatic uveal melanoma,” Cancers, vol. 12, no. 2, p. 405, 2020.

[10] X. Chen, Y. Zang, D. Li et al., “IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era,” Medicine, vol. 99, no. 21, article e19883, 2020.

[11] P. A. Venancio, M. E. L. Consolaro, S. F. Derchain et al., “Indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase expression in HPV infection, SILs, and cervical cancer,” Cancer Cytopathology, vol. 127, no. 9, pp. 586–597, 2019.

[12] L. I. Greene, T. C. Bruno, J. L. Christenson et al., “A role for tryptophan-2,3-dioxygenase in CD8 T-cell suppression and evidence of tryptophan catabolism in breast cancer patient plasma,” Molecular Cancer Research, vol. 17, no. 1, pp. 131–139, 2019.

[13] I. C. Chen, K. H. Lee, Y. H. Hsu, W. R. Wang, C. M. Chen, and Y. W. Cheng, “Expression pattern and clinicopathological relevance of the indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase protein in colorectal cancer,” Disease Markers, vol. 2016, Article ID 8169724, 9 pages, 2016.

[14] N. C. D’Amato, T. J. Rogers, M. A. Gordon et al., “A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer,” Cancer Research, vol. 75, no. 21, pp. 4651–4664, 2015.

[15] S. Li, L. Li, J. Wu et al., “TDO promotes hepatocellular carcinoma progression,” Oncotargets and Therapy, vol. Volume 13, pp. 5845–5855, 2020.

[16] D. Hoffmann, T. Dvorakova, V. Stroobant et al., “Tryptophan 2,3-dioxygenase expression identified in human hepatocellular carcinoma cells and in intratumoral pericytes of most cancers,” Cancer Immunology Research, vol. 8, no. 1, pp. 19–31, 2020.

[17] Q. Liu, J. Zhai, X. Kong et al., “Comprehensive analysis of the expression and prognosis for TDO2 in breast cancer,” Molecular Therapy - Oncolytics, vol. 17, pp. 153–168, 2020.

[18] D. S. Chandrashekar, B. Bashel, S. A. H. Balasubramanyan et al., “UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses,” Neoplasia, vol. 19, no. 8, pp. 649–658, 2017.

[19] M. Platten, D. N. von Knebel, I. Oezen, W. Wick, and K. Ochs, “Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors,” Frontiers in Immunology, vol. 5, p. 673, 2014.

[20] Y. Liu, X. Liang, X. Yin et al., “Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells,” Nature Communications, vol. 8, no. 1, article 15207, 2017.

[21] S. Ren and M. A. Correia, “Heme: a regulator of rat hepatic tryptophan 2,3-dioxygenase?,” Archives of Biochemistry and Biophysics, vol. 377, no. 1, pp. 195–203, 2000.

[22] R. Ma, W. Zhang, K. Tang et al., “Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma,” Nature Communications, vol. 4, no. 1, p. 2508, 2013.

[23] S. A. Lloyd-MacGilp, S. M. Nelson, M. Florin et al., “11β-Hydroxysteroid dehydrogenase and corticosteroid action in Lyon hypertensive rats,” Hypertension, vol. 34, no. 5, pp. 1123–1128, 1999.

[24] J. W. Tomlinson, E. A. Walker, I. J. Bujalska et al., “11beta-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response,” Endocrine Reviews, vol. 25, no. 5, pp. 831–866, 2004.